Low-Dose ARAC, Donor Cells, and GM-CSF for Treatment of Recurrent Acute Myeloid Leukemia After Allogeneic Stem Cell Transplantation

Leukemia - United Kingdom
doi 10.1038/sj.leu.2403412

Related search